ABIVAX Société Anonyme (EPA:ABVX)
96.30
-3.00 (-3.02%)
At close: Mar 11, 2026
ABIVAX Société Anonyme Employees
ABIVAX Société Anonyme had 67 employees as of September 30, 2025. The number of employees increased by 5 or 8.06% compared to the same quarter last year.
Employees
67
Change
5
Growth
8.06%
Revenue / Employee
€79,269
Profits / Employee
€4,380,896
Market Cap
7.50B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 67 | 5 | 8.06% | 67 | 0 |
| Jun 30, 2025 | 69 | 7 | 11.29% | 69 | 0 |
| Mar 31, 2025 | 69 | 8 | 13.11% | 69 | 0 |
| Jun 30, 2024 | 62 | - | - | 62 | 0 |
| Dec 31, 2023 | 61 | 37 | 154.17% | 61 | 0 |
| Dec 31, 2022 | 24 | 0 | - | 24 | 0 |
| Dec 31, 2021 | 24 | -3 | -11.11% | 24 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 700 |
| Cellectis | 222 |
| Genfit | 188 |
| Innate Pharma | 174 |
| Transgene | 147 |
| MedinCell | 145 |
| DBV Technologies | 117 |
| Nanobiotix | 103 |
ABIVAX Société Anonyme News
- 12 hours ago - Harbor Health Care ETF Q4 2025 Portfolio Review - Seeking Alpha
- 1 day ago - Billionaire Steve Cohen Owns Shares of This Stock That Has Soared 1,600% in The Past Year - The Motley Fool
- 12 days ago - 2 Reasons Abivax Stock Could 10X by 2036 - The Motley Fool
- 14 days ago - BTIG Reiterates Buy Rating for Abivax (ABVX) with $150 Price Target | ABVX Stock News - GuruFocus
- 15 days ago - Wedbush Rates Abivax (ABVX) as Underperform with Cautious Outlook - GuruFocus
- 17 days ago - Abivax (ABVX) Highlights Promising Obefazimod Data at ECCO Congress - GuruFocus
- 18 days ago - Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 - GlobeNewsWire
- 22 days ago - Alger Mid Cap Growth Fund Q4 2025 Portfolio Update - Seeking Alpha